Observational study of patients prescribed NORTHERA followed up to 6 months1
Treatment continuation data
Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically. The RESTORE clinical study to assess the sustained effects of NORTHERA therapy in adult patients with symptomatic nOH is ongoing.2,4
1. Francois C, Shibao CA, Biaggioni I, et al. Mov Disord Clin Pract. 2019;6(3):235-242. 2. NORTHERA [package insert]. Deerfield, IL: Lundbeck. 3. Data on file. Deerfield, IL: Lundbeck. 4. U.S. National Library of Medicine. Sustained effect of droxidopa in symptomatic neurogenic orthostatic hypotension (RESTORE). Clinical Trials website. https://clinicaltrials.gov/ct2/show/results/NCT02586623. Accessed July 21, 2020.
Indications and Usage
NORTHERA (droxidopa) is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson’s disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically.
Important Safety Information
WARNING: SUPINE HYPERTENSION
Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses. Elevating the head of the bed lessens the risk of supine hypertension, and blood pressure should be measured in this position. If supine hypertension cannot be managed by elevation of the head of the bed, reduce or discontinue NORTHERA.
WARNINGS AND PRECAUTIONS
USE IN SPECIFIC POPULATIONS
For more information, please see the full Prescribing Information, including Boxed Warning for supine hypertension.